Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer

Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study

“…These results suggest that patients under anti-CD20 treatment may still be protected to some extent from severe courses of COVID-19, even if SARS-CoV-2 infection per se cannot be prevented in the absence of neutralizing antibodies. Moreover, although our data and a previously published report [36] showed that antibody levels diminished in the months after the second dose in patients with cancer, data from other vaccinations imply that vaccination-specific memory T cells may persist for decades after immunization [37]. Along these lines, a long-acting monoclonal antibody was recently approved for use as pre-exposure prophylaxis in patients with compromised immune systems due to immunosuppressive medications who are not able to mount an adequate immune response to COVID-19 vaccination [38].…”

Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies

“…Patients treated with systemic corticosteroids mount a lower humoral response to vaccination, including that against SARS-CoV-2. Studies on patients with musculoskeletal diseases, cancer, and on transplant recipients documented that long-term treatment with oral corticosteroids induce a lower antibody response to mRNA-based vaccines [ 17 , 18 , 19 ]. However, whether the prolonged use of ICS has any immunosuppressive properties, and specifically if ICS affects the humoral response to vaccines, is unclear, especially in pwCF.…”

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

“…We had previously reported on the immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Tozinameran) in a large cohort of patients with cancer after the first and the second doses [ 1 ], and we subsequently showed the rapid decline of humoral response over the time until 6 months of follow-up [ 2 , 3 ]. We have also recently reported on the potentiation of humoral response after the third dose in this frail population [ 4 ], in line with other studies [ [5] , [6] , [7] , [8] , [9] ].…”